MERTK inhibition resulted in increased sensitivity of head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), and non-small-cell lung carcinoma (NSCLC) cell lines to AXL inhibition. This evidence concerns the gene MERTK and triple-negative breast carcinoma.